Tags

Type your tag names separated by a space and hit enter

Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: prolonged release approach for the treatment of rheumatoid arthritis.
Drug Deliv. 2011 Apr; 18(3):198-207.DD

Abstract

The use of glucocorticoids in the treatment of rheumatoid arthritis has been widely employed, but, owing to their systemic side-effects and also their susceptibility to the first pass metabolism, their use is being discouraged. To circumvent this, triamcinolone (TA) were encapsulated in chitosan microspheres with glutaraldehyde as the cross-linking agent to achieve a prolonged drug release. The percentage of drug loading, encapsulation efficiency, and surface morphology by Scanning electron microscopy (SEM), Phase transition by Differential scanning colorimetry (DSC), as well as Fourier transform infrared spectroscopy (FTIR) studies was carried out to characterize the chitosan microspheres. In-vitro and in-vivo release studies revealed that microspheres were able to control the release of TA with a uniform release pattern up to a period of 36 days and thereafter an extended release up to 63 days. The clinical parameters were investigated for changes in paw volume, hematological parameters like Erythrocyte sedimentation rate (ESR), Paced cell volume (PCV), Total leucocyte count (TLC), Hb, and Differential cell count (DCC) in Fruend's complete adjuvant induced arthritic rats. Histopathological findings as well as radiology (X-ray) further confirmed the effectiveness of TA encapsulated microspheres in mitigating the rat arthritic model.

Authors+Show Affiliations

Research Lab, GIET School of Pharmacy, NH-5, Chaitanya Nagar, Rajahmundry-533 294, India. mddhanaraju@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21028952

Citation

Dhanaraju, Magharla Dasaratha, et al. "Triamcinolone-loaded Glutaraldehyde Cross-linked Chitosan Microspheres: Prolonged Release Approach for the Treatment of Rheumatoid Arthritis." Drug Delivery, vol. 18, no. 3, 2011, pp. 198-207.
Dhanaraju MD, Elizabeth S, Gunasekaran T. Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: prolonged release approach for the treatment of rheumatoid arthritis. Drug Deliv. 2011;18(3):198-207.
Dhanaraju, M. D., Elizabeth, S., & Gunasekaran, T. (2011). Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: prolonged release approach for the treatment of rheumatoid arthritis. Drug Delivery, 18(3), 198-207. https://doi.org/10.3109/10717544.2010.528069
Dhanaraju MD, Elizabeth S, Gunasekaran T. Triamcinolone-loaded Glutaraldehyde Cross-linked Chitosan Microspheres: Prolonged Release Approach for the Treatment of Rheumatoid Arthritis. Drug Deliv. 2011;18(3):198-207. PubMed PMID: 21028952.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: prolonged release approach for the treatment of rheumatoid arthritis. AU - Dhanaraju,Magharla Dasaratha, AU - Elizabeth,Sheela, AU - Gunasekaran,Thirumurugan, Y1 - 2010/10/28/ PY - 2010/10/30/entrez PY - 2010/10/30/pubmed PY - 2011/7/13/medline SP - 198 EP - 207 JF - Drug delivery JO - Drug Deliv VL - 18 IS - 3 N2 - The use of glucocorticoids in the treatment of rheumatoid arthritis has been widely employed, but, owing to their systemic side-effects and also their susceptibility to the first pass metabolism, their use is being discouraged. To circumvent this, triamcinolone (TA) were encapsulated in chitosan microspheres with glutaraldehyde as the cross-linking agent to achieve a prolonged drug release. The percentage of drug loading, encapsulation efficiency, and surface morphology by Scanning electron microscopy (SEM), Phase transition by Differential scanning colorimetry (DSC), as well as Fourier transform infrared spectroscopy (FTIR) studies was carried out to characterize the chitosan microspheres. In-vitro and in-vivo release studies revealed that microspheres were able to control the release of TA with a uniform release pattern up to a period of 36 days and thereafter an extended release up to 63 days. The clinical parameters were investigated for changes in paw volume, hematological parameters like Erythrocyte sedimentation rate (ESR), Paced cell volume (PCV), Total leucocyte count (TLC), Hb, and Differential cell count (DCC) in Fruend's complete adjuvant induced arthritic rats. Histopathological findings as well as radiology (X-ray) further confirmed the effectiveness of TA encapsulated microspheres in mitigating the rat arthritic model. SN - 1521-0464 UR - https://www.unboundmedicine.com/medline/citation/21028952/Triamcinolone_loaded_glutaraldehyde_cross_linked_chitosan_microspheres:_prolonged_release_approach_for_the_treatment_of_rheumatoid_arthritis_ L2 - https://www.tandfonline.com/doi/full/10.3109/10717544.2010.528069 DB - PRIME DP - Unbound Medicine ER -